TB-500 vs BPC-157: A Research-Grade Comparison for Labs
BPC-157 and TB-500 are distinct research peptides. BPC-157 is a 15-amino-acid peptide. The TB-500 material listed by Vertex Labs is the N-terminally acetylated seven-amino-acid fragment Ac-LKKTETQ. It should not be described as full-length thymosin beta-4 or assigned the full-length peptide’s 43-residue chain.
BPC-157 and TB-500 are distinct research peptides, differing primarily in their amino acid composition and structure. BPC-157 is a longer peptide, composed of 15 amino acids. In contrast, the TB-500 material supplied by Vertex Labs is a shorter, N-terminally acetylated seven-amino-acid fragment identified as Ac-LKKTETQ.
The useful comparison begins with identity: which sequence and modification does the research protocol specify, and what does the corresponding batch documentation establish? Peptide length alone does not establish which material is more stable, easier to analyze, or appropriate for a particular experiment.
For research use only. Not for human or veterinary use.
BPC-157 vs TB-500: compound identity
| Field | BPC-157 | TB-500 listed by Vertex Labs |
|---|---|---|
| Peptide length | 15 amino acids | 7 amino acids, with N-terminal acetylation |
| Identity reference | BPC-157, PubChem CID 9941957 | Ac-LKKTETQ, a fragment corresponding to residues 17–23 of thymosin beta-4 |
| Listed presentations | 5 mg and 10 mg | 5 mg and 10 mg |
| Supplied form | Lyophilized research material | Lyophilized research material |
| Product details | BPC-157 specifications and batch documentation | TB-500 specifications and batch documentation |
These are product-listing identifiers, not a substitute for testing a supplied sample. Compare the vial label and current specification with the report for the corresponding batch.
TB-500 is not the same identity as full-length thymosin beta-4
Esposito and colleagues identified Ac-LKKTETQ in the TB-500 preparation they studied in 2012. Their work characterized the acetylated 17–23 fragment using analytical methods and a synthesized comparison material. Read the original identification study.
That publication establishes the identity of the material investigated in that study. It does not independently verify a Vertex Labs batch. For procurement, confirm the exact sequence, modification, and scope of the available lot documentation rather than relying on the TB-500 name alone. Evidence concerning full-length thymosin beta-4 should not automatically be attributed to its acetylated fragment.
What does the analytical research tell us?
A 2024 study developed an analytical method for TB-500 and its metabolites in experimental systems. It examined the parent Ac-LKKTETQ compound and specific metabolites, with results tied to the methods and models used. Read the TB-500 metabolite study.
This is not a head-to-head demonstration that TB-500 is generally preferable to BPC-157. A longer detection window for a metabolite in one experimental setting does not establish greater storage stability of the parent compound. Likewise, residue count alone does not establish that BPC-157 is more suitable for long-term reference storage.
Choose the material specified by the research question and evaluate whether the published method applies to that exact identity and sample matrix. Neither a product listing nor this comparison establishes human outcomes.
How to review a BPC-157 or TB-500 COA
- Match the sample: confirm the compound, presentation, and lot number against the vial label.
- Identify the report: locate the laboratory, report identifier, and relevant dates.
- Read the method: check what analytical method was used for each reported result.
- Separate measurements: do not treat a purity percentage as an identity confirmation or a measured peptide amount. Read the units and meaning of each result.
- Resolve gaps: ask for clarification when an analysis required by your laboratory is not included.
Do not assume every report includes mass spectrometry, net peptide content, residual solvent results, or the same set of tests. Refer to the individual document. Reports apply to the tested sample and analyses stated in them.
How should labs store BPC-157 and TB-500 and manage material records?
Follow the product label and applicable laboratory procedures. Keep receipt, lot, and storage records linked to the corresponding material. If packaging is damaged or handling conditions are uncertain, resolve the discrepancy before relying on the material.
This comparison does not assign a universal storage lifetime, solvent, or preparation procedure to either compound. Those decisions require information applicable to the exact material and laboratory workflow.
Where to find product and batch documentation
The BPC-157 product page and TB-500 product page list the available presentations, current specifications, and batch-documentation access. Review each product separately, even when both are being considered for the same research project.
Additional documents are available through the COA database. Read the Testing Standards for Vertex Labs’ published review framework.
What are the key takeaways for BPC-157 and TB-500 research?
- BPC-157 and the Ac-LKKTETQ TB-500 fragment have different identities and are not interchangeable.
- Do not substitute full-length thymosin beta-4 data for fragment-specific evidence.
- Confirm presentation, lot, and analytical scope from the corresponding documentation.
- Vertex Labs materials are supplied exclusively for laboratory research, not human or veterinary use.
Sources
- PubChem: BPC-157, CID 9941957.
- Esposito S. et al. (2012). Identification and characterization of the acetylated thymosin beta-4 fragment in TB-500. PubMed 22962027.
- Rahaman K. A. et al. (2024). Analytical characterization of TB-500 and its metabolites. PubMed 38382158.